Christopher Viehbacher

Sanofi-Aventis Launches Hostile Bid for Genzyme

After months of courting U.S. drugmaker Genzyme, French pharmaceutical company Sanofi-Aventis launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all outstanding shares of Genzyme common stock.